WO2009108755A3 - Pharmaceutical combinations for the treatment of cancer - Google Patents

Pharmaceutical combinations for the treatment of cancer Download PDF

Info

Publication number
WO2009108755A3
WO2009108755A3 PCT/US2009/035249 US2009035249W WO2009108755A3 WO 2009108755 A3 WO2009108755 A3 WO 2009108755A3 US 2009035249 W US2009035249 W US 2009035249W WO 2009108755 A3 WO2009108755 A3 WO 2009108755A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treatment
pharmaceutical combinations
relates
inhibitor
Prior art date
Application number
PCT/US2009/035249
Other languages
French (fr)
Other versions
WO2009108755A2 (en
Inventor
Carlo Gambacorti
Luca Mologni
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of WO2009108755A2 publication Critical patent/WO2009108755A2/en
Publication of WO2009108755A3 publication Critical patent/WO2009108755A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Abstract

This invention relates to pharmaceutical compositions for the treatment of cancer comprising a src kinase inhibitor and an HDAC inhibitor. It also relates to methods of treating cancer in a mammal by administering a src kinase inhibitor in comnbination with an HDAC inhibitor.
PCT/US2009/035249 2008-02-27 2009-02-26 Pharmaceutical combinations for the treatment of cancer WO2009108755A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6742208P 2008-02-27 2008-02-27
US61/067,422 2008-02-27

Publications (2)

Publication Number Publication Date
WO2009108755A2 WO2009108755A2 (en) 2009-09-03
WO2009108755A3 true WO2009108755A3 (en) 2013-06-13

Family

ID=41016701

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/035249 WO2009108755A2 (en) 2008-02-27 2009-02-26 Pharmaceutical combinations for the treatment of cancer

Country Status (1)

Country Link
WO (1) WO2009108755A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691534B2 (en) 2006-12-29 2014-04-08 Celgene Corporation Preparation of romidepsin

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2366398A1 (en) * 2010-03-17 2011-09-21 Deutsches Krebsforschungszentrum Cancer therapy with a parvovirus combined with an HDAC inhibitor
EP3034076B1 (en) * 2013-08-13 2020-09-30 JC (Wuxi) COMPANY, Inc. Combined application of isothiocyanate compound and anti-cancer medicine
JP7136807B2 (en) 2017-04-17 2022-09-13 ザ・ユニバーシティ・オブ・シカゴ Polymeric materials for the intestinal delivery of short-chain fatty acids for therapeutic applications in human health and disease
CN109758461A (en) * 2019-02-26 2019-05-17 沈锋 Application of the bosutinib as the inhibitors of enzymes of ASPH

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008017024A2 (en) * 2006-08-02 2008-02-07 Universtiy Of South Florida Method of treating chronic myelogenous leukemia cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008017024A2 (en) * 2006-08-02 2008-02-07 Universtiy Of South Florida Method of treating chronic myelogenous leukemia cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FISKUS W ET AL: "Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 108, no. 2, 15 July 2006 (2006-07-15), pages 645 - 652, XP008131474, ISSN: 0006-4971, [retrieved on 20060314], DOI: 10.1182/BLOOD-2005-11-4639 *
MOLOGNI LUCA ET AL: "Valproic acid enhances bosutinib cytotoxicity in colon cancer cells.", 15 April 2009, INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER 15 APR 2009, VOL. 124, NR. 8, PAGE(S) 1990 - 1996, ISSN: 1097-0215, XP002695031 *
NIMMANAPALLI R ET AL: "Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 101, no. 8, 15 April 2003 (2003-04-15), pages 3236 - 3239, XP002263976, ISSN: 0006-4971, DOI: 10.1182/BLOOD-2002-08-2675 *
U.S. NATIONAL INSTITUTES OF HEALTH: "A Multi-Arm Complete Phase 1 Trial of Valproic Acid-based 2-Agent oral Regimens for patients with advanced solid tumors", 2 July 2007 (2007-07-02), XP002695032, Retrieved from the Internet <URL:http://clinicaltrials.gov/archive/NCT00495872/2007_07_02> [retrieved on 20130409] *
WARREN FISKUS ET AL: "Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 12, no. 19, 1 October 2006 (2006-10-01), pages 5869 - 5878, XP002672182, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-06-0980 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691534B2 (en) 2006-12-29 2014-04-08 Celgene Corporation Preparation of romidepsin

Also Published As

Publication number Publication date
WO2009108755A2 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2014062720A3 (en) Methods of treating cancer
WO2009089494A3 (en) Pharmaceutical compositions
IL206970A0 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
HK1159498A1 (en) Methods and compositions for the treatment of cancer
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EP2361089A4 (en) Compositions and methods for the treatment of altered -synuclein function
EP2313091A4 (en) Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
WO2007081751A9 (en) Compositions and methods for the treatment of cancer
WO2012024530A3 (en) Therapeutic peptide-polymer conjugates, particles, compositions, and related methods
WO2010083385A3 (en) Compounds for reducing drug resistance and uses thereof
WO2010033977A3 (en) Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
EP2049151A4 (en) Methods and compositions for the treatment of cancer
EP2340027A4 (en) Methods and compositions for the treatment of cancer
WO2007059154A3 (en) Treatment of cancers with acquired resistance to kit inhibitors
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
WO2011129936A3 (en) Compositions and methods for the prevention and treatment of cancer
WO2009120810A3 (en) Neurodegenerative disorders
WO2012073047A3 (en) Compositions and methods
IL214349A0 (en) Compositions and methods for the treatment of cancer
WO2010077339A3 (en) β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
WO2009108857A3 (en) Combination therapy for prostate cancer
WO2010141956A3 (en) Methods and compositions for the treatment of cancer
EP2150270A4 (en) Methods and compositions for the treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09713716

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09713716

Country of ref document: EP

Kind code of ref document: A2